This study will be a prospective randomized, double-blinded, placebo-controlled trial of patients undergoing primary hip arthroscopy for FAIS and/or labral pathology. All patients who sign the consent form will be enrolled in the study and randomized to one of the two treatment arms. Follow-up will take place at 1-month, 3-months, 6-months, and 1-year.
No linked publications found in PubMed
Inclusion Criteria: * Adult patients 18-40 * English-speaking * Clinical and radiographic examination (MRI) consistent FAIS and/or labral pathology, and are schedule for primary hip arthroscopy * Written and informed consent for study participation Exclusion Criteria: * Patients younger than 18 or older than 40 years of age * Non-native English speaker * Revision surgery or prior history of ipsilateral hip or knee surgery * Inability to comply with the proposed follow-up clinic visits * Patients lacking decisional capacity * Patients with a history of deep vein thrombosis, pulmonary embolism, or known clotting disorder or hypercoagulable state * Pregnant or breast-feeding women. Pregnancy as determined by a positive pregnancy test prior to procedure. Females of childbearing potential must agree to use an acceptable birth control method during study participation. * Worker's compensation patients * Any clinically significant finding that would place the patient at health risk, impact the study, or affect the completion of the study * Any psychiatric illness that would prevent comprehension of the details and nature of the study and interfere with follow-up clinic visits